MedTrace Logo

Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu

NCT00347529 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2007-01-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given, any effects it may have on subjects' wellbeing and whether it can produce antibody responses in the body that may protect against the subjects catching a pandemic strain of flu

Conditions

  • Influenza (Pandemic)

Interventions

BIOLOGICAL

pPML7789 with and without pPJV2012 administered by PMED

Sponsors & Collaborators

  • PowderMed

    lead INDUSTRY

Principal Investigators

  • Tim Mant, BSc, FRCP, FFPM · Guys Research Drug Unit, Quintiles UK Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Completion
2007-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347529 on ClinicalTrials.gov